Novo Nordisk A/S (NVO)

Revenue

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Ozempic Pill / Rybelsus Revenue	20.04B	22.09B	23.30B
Ozempic Injectable Revenue	120.73B	127.09B	120.34B
Victoza Revenue	1.02B	3.02B	5.48B
Total GLP-1 Revenue	141.79B	152.20B	149.13B
Long-Acting Insulin Revenue	17.72B	18.76B	19.10B
Premix Insulin Revenue	10.11B	10.32B	10.79B
Fast-Acting Insulin Revenue	17.91B	18.58B	18.52B
Human Insulin Revenue	4.51B	5.48B	6.97B
Total Insulin Revenue	50.25B	53.14B	55.37B
Other Diabetes Care Revenue	2.22B	1.77B	2.12B
Total Diabetes Care Revenue	194.26B	207.11B	206.62B
Wegovy Injectable Revenue	79.99B	79.11B	58.21B
Saxenda Revenue	1.80B	3.24B	6.94B
Total Obesity Care Revenue	92.66B	82.35B	65.15B
Diabetes & Obesity Care Revenue	286.92B	289.46B	271.76B
Rare Blood Disorders Revenue	11.60B	11.96B	12.14B
Rare Endocrine Disorders Revenue	6.51B	5.96B	4.99B
Other Rare Disease Revenue	1.86B	1.69B	1.51B
Rare Disease Revenue	19.98B	19.61B	18.64B
Revenue (Total)	333.65B	309.06B	290.40B

Revenue by Geography

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
US Revenue	162.88B	173.17B	167.40B
EUCAN Revenue	75.10B	66.09B	57.55B
Emerging Markets Revenue	30.12B	30.44B	29.52B
APAC Revenue	20.23B	20.71B	17.44B
China Revenue	18.56B	18.66B	18.50B
Total International Revenue	144.01B	135.90B	123.00B
Revenue (Other)	-117.25B	-135.90B	-123.00B
Revenue (Total)	333.65B	309.06B	290.40B

Revenue by Geography 2

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
US Revenue (Pre-FY2024 Reporting)	-	-	167.40B
Other North American Operations (NAO) Revenue	-	-	10.77B
Total North American Operations (NAO) Revenue	-	-	178.17B
EMEA Revenue	-	-	60.40B
China Revenue (Pre-FY2024 Reporting)	-	-	18.50B
Rest of World Revenue	-	-	33.33B
Revenue (Total)	333.65B	309.06B	290.40B

EBIT

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Diabetes & Obesity Care Operating Profit	138.98B	126.45B	127.72B
Rare Disease Operating Profit	2.45B	1.21B	620.00M
Operating Income (Total)	141.43B	127.66B	128.34B

Data Source: Fiscal.ai Last updated: Nov 6, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error